

Meeting Title: Research and Continuous Improvement Committee Meeting

Date: August 7, 2026

Time: 9:00AM—11:00AM

Location / Platform: Online Teams

Committee Chair: Dan Jennings

Note Taker: Leslie Peterson, NMDOH Medical Psilocybin Program

IMPORTANT REMINDER:

This meeting was recorded. For specific details pertaining to the meeting, please refer to the recording located on the Medical Psilocybin Advisory Board Website @ [https://www.nmhealth.org/about/mcpp/Medical Psilocybin Program/mpab/](https://www.nmhealth.org/about/mcpp/Medical%20Psilocybin%20Program/mpab/)

Attendees:

Research and Continuous Improvement Committee Chair: Dan Jennings

Department of Health Staff:

- Dominick Zurlo
- Robert Truckner, MD
- Brenda Martinez
- Cyrus Rautman
- Leslie Peterson
- Cathy Augeri
- Katy Freytag
- Adrian Estrada
- Vicente Roybal

Participants and Public Attendees:

- Nathan Oakes
- Ian Dunn
- Chris Peskuski
- Esteban Garcia
- Jason Brooks
- Brenda Burgard, LPCC, LSAA, ATR
- Catherine Sanchez, WCA
- Senator Jeff Steinborn
- Gregory Evans
- Kate Hawke

- Don Moser
- Hanifa Nayo Washington
- Skye Rivers

Call to Order

- At 9:00AM the meeting was called to order by Dominick Zurlo.
- Dominick opened the meeting and reminded attendees of proper public meeting etiquette and the public meeting being recorded and publicly posted.
- Introductions: RACI Committee members and public participants
- Introductions: Department of Health Medical Psilocybin Program Staff

Approval of Prior Minutes

- Approved as submitted

Agenda Items

- Presentation by Nathan Oakes: Cloud, DevOps, and cybersecurity engineer and technical leader with nearly three decades of experience designing and operating secure, resilient technology systems.
 - Trust by Design
 - The Human Stakes
 - The Data Landscape
 - Working Vocabulary
 - Quasi Identifiers
 - Three Lenses: 1. Security 2. Privacy 3. Governance
 - Controlled Re-Linking
 - Re-identification Must be Exceptional and Governed
 - Ethical Center
 - Patient Data Should Serve the Patient
 - Patient-level information collected through participation in the Medical Psilocybin Program should never become a commercial data asset.
 - The patient's intimate information should never become the product.
 - Progressive Disclosure
 - Enable Research without Exposing People
 - Policy Questions
 - What New Mexico Should Define Now
 - Permitted purposes
 - Prohibited uses

- Data crossing each boundary
 - Re-identification rules
 - Auditability requirements
 - Downstream obligations
 - Patient rights and explanations
 - Periodic review
- Protect the person
- Protect the data
- Preserve the value
- Research and Continuous Improvement Committee Purpose and Responsibilities were reviewed.
- Purpose: Ensure practitioner preparation, research activities, harm-reduction practices and program evaluation for medical psilocybin services in NM are grounded in scientific evidence, ethical standards and continuous quality improvement principles.
- Responsibilities:
 - Recommend guidelines for research and data collection:
 - Core data elements
 - Outcome monitoring and adverse event reporting standards
 - Ethical research practices
 - Evaluation frameworks
 - Recommend harm-reduction and quality improvement practices:
 - Risk-screening & medication interaction guidance
 - Emergency preparedness & crisis response
 - Informed consent & patient education materials
 - Mechanisms for updating standards as new evidence emerges.
- Wisdom and Collaboration: Everyone has wisdom and that provides for the wisest results. Each of us will:
 - Use voice and allow others to use voice
 - Hear others and be heard
 - Avoid assumptions and ask questions
 - Reach minimally, act maximally
- Proposed Harm Reduction/Quality Improvement Framework
 - Tier 1: Routine/No Incident
 - Tier 2: Challenging Experience Requiring Added Support
 - Tier 3: Adverse Event with Clinical Significance
 - Tier 4: Serious Adverse Event Requiring External Response or Formal Review

- The RACI Committee voted unanimously to move forward with the proposed recommendations to present to the Advisory Board and the Department.

Announcements/Updates/Public Comment Process

- Written public comments may be submitted to: medical.psilocybin@doh.nm.gov
- Include the committee's name in the subject line.
- If referencing open-source documents, such as peer-reviewed journal articles:
 - Do not include the document, only a working - accessible hyperlink;
 - Documents must be sent with context provided (i.e. do not simply send a research article);
- The comment must relate to the topics discussed in the meeting.
- Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.
- Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) in the documents.
- To be included, please send your comment by 5:00 PM the business day after the meeting.

Next Meetings

Advisory Board Meeting:

- Friday, August 14, 2026, 1:00pm—3:00pm

Committee Meetings:


- End of Life Care – Friday August 14, 2026 @ 9:00AM—11:00AM:
 - Larry Leeman, Chair
- Equity Access and Cultural Consideration – Tuesday August 18, 2026 @ 2:00pm—4:00PM:
 - DezBaa, Chair
- Dosage, Administration & Clinical Practice – Wed. August 19, 2026 @ 1:00pm—2:00pm:
 - Ian Dunn, Chair
- Training and Education – Friday August 21, 2026 @ 9:00AM-11:00AM:
 - Brenda Burgard, Chair
- Research & Continuous Improvement – Friday Sept. 11, 2026 @ 9:00AM—11:00AM:
 - Dan Jennings, Chair
- Patient Qualification & Safety – Monday October 5, 2026 @ 9:00AM—11:00AM:
 - Ian Dunn, Chair

Adjournment


- Meeting adjourned at 10:40am

Public Comments submitted via Teams Meeting Chat or by email

- Zurlo, Dominick, DOH 09:02am
 - Contact information:
 - Email: Medical.Psilocybin@doh.nm.gov
 - Program Website: <https://www.nmhealth.org/about/mcpp/mpp/>
 - Advisory Board Website: <https://www.nmhealth.org/about/mcpp/mpp/mpab/>
- Medical Psilocybin
- How to raise your hand to speak:
- If on a computer – click on the “hand” icon near the top of the Teams window (it says “Raise” under the icon)



- If on the Teams app on a phone, please press the ellipses (three dots) in the menu and then the “hand” icon will appear, and you can select it



- If you are joining through voice only on a phone, press *5 to raise or lower your hand
- How to Unmute:
 - Once your name is called, you will be able to unmute:
 - To unmute/mute on Teams on a Computer or on the Teams Phone App click on the microphone icon:



- On a computer it is in the upper right area of the Teams window.
- On a phone it is usually in the lower left of the Teams App, however, different models of phone (Apple, Android, etc.) may have the mute/unmute icon in a different location:
- Telephone: voice only - press *6 to unmute/mute
- Kate Hawke 09:03am Good morning, everyone 😊 Kate Hawke from Santa Fe. Trauma therapist with 20+ years working with psychedelic harm reduction.
- Catherine Sanchez WCA 09:05am Cathy Sanchez, Bureau Chief at Workers' Compensation Administration, Medical Cost Containment

- Hanifa Nayo 09:05am Hanifa Nayo Washington- Co-Director of the Psychedelic Mental Health Access Alliance - Santa Fe Implementation Partner of the UNM Group Psilocybin Assisted Therapy Study for PTSD.
- Gregory Evans 09:06am Gregory Evans independent researcher and home mycologist Santa FE
- Skye Rivers, SFR 09:07am Skye Rivers, Santa Re Reporter covering updates on the legalization of psilocybin from Santa Fe
- Jason Brooks 09:07am Jason Brooks - Policy Analyst Divisions of Cannabis in Missouri. Here in observation in prep for legislation in MO.
- Nathan Oakes - ENFAM Labs 09:07am Nathan Oakes - ENFAM Labs
- Cloud, DevOps, and cybersecurity engineer and technical leader with nearly three decades of experience designing and operating secure, resilient technology systems. I support digital health initiatives for the U.S. Department of Veterans Affairs, with a focus on cloud architecture, data protection, identity and access management, compliance, and technical risk. I specialize in translating complex security and data-governance issues into practical guidance for technical leaders, policymakers, and program stakeholders.
- Dominick Zurlo, DOH 09:30am Thank you, Nathan!
- Gregory Evans 09:30am Thank you sir!
- Dominick Zurlo, DOH 09:35am Link directly to the statute:
<https://nmonesource.com/nmos/nmsa/en/item/4355/index.do#a2D>
- Kate Hawke 09:53am Good work, thanks to everyone who worked on this.
- Jason Brooks 09:58am Really impressive.
- Skye Rivers, SFR 10:02am well done...
- Sye Rivers, SFR 10:08am I think this information needs to be shared, but I do agree with Ian.
- Gregory Evans 10:34am gregory.L.evans@gmail.com interstitial workgroups will be Mondays at noon through the month of August
- Dominic Zurlo, DOH 10:35am
 - How to submit written public comments:
 - Please send written public comment to the program email at: medical.psilocybin@doh.nm.gov and include the committee's name in the subject line.
 - If referencing documents from other sources/websites:
 - Do not include the document, only a working - accessible hyperlink;
 - Documents must be sent with context provided (i.e. do not simply send a research article);
 - The comment must relate to the topics discussed in the meeting.
 - Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.
 - Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) in the documents.
 - To be included, please send your comment by 5:00 PM the business day after the meeting.
- Esteban Garcia 10:35am This may be a bit off topic so if it can't be covered in this meeting that's fine. Is there any active research in micro-dosing? Thank you
- G-Ian.Dunn 10:40am Thank you everyone for coming and thank you to everyone who presented and created everything for us today
- 10:40am Recording stopped